Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.59 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.59 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.59 |
| ▸ | ITGAV | P06756 | 1/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.59 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.59 |
| ▸ | ITGAL | P20701 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | IDE | P14735 | 2/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385148 | 1.00 | ITGB1 (0.59) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL7264417 | 0.88 | ITGB1 (0.63) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL197943 | 0.79 | ITGB1 (0.40) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL14141170 | 0.75 | ITGB1 (0.47) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL2582193 | 0.74 | TDP1 (0.45) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL27049775 | 0.74 | ITGB1 (0.47) | ITGB1ITGA5ITGB3ITGB2ITGAV | |
| SCHEMBL11032630 | 0.74 | — | — | |
| SCHEMBL3102769 | 0.74 | — | — | |
| SCHEMBL11212045 | 0.74 | — | — | |
| SCHEMBL1114601 | 0.73 | ITGB1 (0.50) | ITGB1ITGA5ITGB3ITGB2ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416799-B1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | TUFTS MEDICAL CT INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170065668-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| EP-2990051-B1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | TUFTS MEDICAL CT INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3061460-A1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | Tufts Medical Center, Inc. (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9376499-B2 | PAR-1 activation by metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2990051-A1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | Tufts Medical Center, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150023975-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-22 | — | — | US | disclosed |
| US-8906844-B2 | Immunomodulatory peptides | BIOGEN IDEC HEMOPHILIA INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120121706-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| EP-1370276-B1 | INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS AND THEIR MEDICAL USE | ZEALAND PHARMA AS (DK) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048488-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-7585839-B2 | Cyclic and linear oligopeptides; capable of increasing gap junction conductance; lack the proarrhythmic side effects; use as drug to also treat eye disorders, cancer, and gastrointestinal disorders among others | ZEALAND PHARMA A/S (DK) | 2009-09-08 | — | — | US | disclosed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20050113293-A1 | Medical uses of intercellular communication facilitating compounds | ZEALAND PHARMA A/S | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121706-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, PLAT, F2RL1 | ITGB1 411/4885ITGA5 473/4885ITGB3 565/4885 |
| US-20170065668-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, F2RL1, PLAT | ITGB1 391/4885ITGA5 481/4885ITGB3 562/4885 |
| US-20150023975-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, F2RL1, PLAT | ITGB1 391/4885ITGA5 481/4885ITGB3 562/4885 |
| US-20050113293-A1 | Medical uses of intercellular communication facilitating compounds | GJB2, GJA1, TNNI3 | ITGB1 1862/4885ITGA5 1907/4885ITGB3 1066/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | ITGB1 876/4885ITGA5 338/4885ITGB3 588/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | ITGB1 876/4885ITGA5 338/4885ITGB3 588/4885 |
| US-20100048488-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | ITGB1 1659/4885ITGA5 945/4885ITGB3 1218/4885 |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | ITGB1 1375/4885ITGA5 672/4885ITGB3 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.